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1. Introduction 
Although the origins of cancer can be exceptionally complex due to the range of genes that 
may be involved it is also apparent that there are “consensus” genes, ones that are 
frequently mutated. The AP-1 family of transcription factors represent a set of proteins that 
are commonly involved in cancers as well as other developmental and pathological 
conditions including heart development, apoptosis, and hepatogenesis (reviewed in (1). 
Although defined as a protein that can bind to a consensus sequence in a variety of 
promoters, AP-1 is in fact a series of heterodimmers that are created between at least 7 
distinct proteins including c-jun, junB, Fos, FosB, Fra1,Fra2 and the Maf family of proteins 
(2). Each of these proteins is the product of distinct genes and although they are different at 
the amino acid level they share homology and structural similarities including a leucine 
zipper, transactivation domain and a basic region. Expression of these different proteins is 
tightly controlled and they may be expressed at different times of development and in 
different tissues. Control of AP-1 activity revolves around the control of these protein’s 
transcription, translation and post-translation modification 
There have been several reports that have detailed the role that some of the family members 
may play in several tumors. Through the use of dominant negative mutants for c-jun it has 
been demonstrated that this protein is necessary for tumor survival while inhibition of jun-B 
may enhance tumor survival (3-5). In all of these experiments it is not clear if any of the 
other family members that comprise AP-1 are actually present in the cell and if they might 
play roles as well. Instead of developing dominant negative mutants that could mask the 
role that the other family members play in tumorigenesis we have taken the approach of 
creating a series of either siRNAs or shRNAs to investigate the role that each of these family 
members play in a glioblastoma cell line. Our results demonstrate that in the U87-MG cell 
line all family members are expressed. However the necessity of each these members varies 
greatly for cell proliferation and survival.  
2. Materials and methods 
Cells and transfections: Cell lines U87-MG, U118-MG and U373-MG were obtained from the 
American Type Culture Collection and maintained according to their instructions. Cells 
transfections, selections in geneticin sulfate and secreted alkaline phosphatase assays were 
performed as essentially as  described (6) 
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shRNA: siRNAs were developed by Elbashir using the methods described by (7, 8). At 63-
190 nucletoides downstream of the start codon a 19 nucleotide sequence was chosen. This 
sequence began with an adenine dimer and had a 47-80% GC content. Controls were 
created from these sequences by randomizing the order of the bases. Both the selected 
shRNA sequence and its cognate control were compared to the nucleotide databases at the 
National Institute for Biotechnoilogy using the BLAST program (9). Only those sequences 
that were unique were used for oligonucleotides synthesis. These sequences were then 
used to direct the synthesis of oligonucleotides. In addition to the shRNA sequences these 
oligonucleoitides contained a short region that resulted in a hairpin region. 
Oligonucleotides were ligated into pBluescript that contained an H1 promoter (10) and 
pSuperiorneo (Oligoengines). Clones were verified by sequence analysis. 
Cell growth assays. Cells were seeded into 96 well plates. On day 0 cells were dosed with 
media that contained the control solvent or media that contained 2μg/ml doxycycline . 
Medium was replenished every 2 days thereafter with the appropriate additions. Cell 
division was determined using the 10 μl per well of CCK8 (Dojindo) a formazan dye based 
assay. After 1 hour of incubation with the dye the amount of dye converted was measured 
by spectrophotometry at a wavelength of 459 nm.  
Western blots. Western blots were performed essentially as described (6). Protein amounts 
in each sample were determined using the BCA assay (Pierce) with bovine serum albumin 
as a standard. Antibodies to c-jun, c-fos (Upstate Biotechnologies) JunB, JunD, FosB, Fra-1 
and Fra-2 (Santa Cruz), and cleaved PARP (Cell Signalling Technologies) were purchased. 
Caspase assays. Assays for activated caspase 3 and 7 were performed using the Apo-ONE 
kit (Promega). Lysates from induced cells were compared to cells that were not induced 
with 2μg/ml of doxycyclin. Assays were read on a Perkin Elmer LS-50B fluorometer with an 
excitation wavelength of 485nm and an emission wavelength of 530nm according to 
manufacturer’s recommendations. 
3. Results 
To determine if the transcription factor AP-1 was present at elevated levels in glioblastomas 
we transfected a reporter plasmid, pAP-1SEAP, or a control plasmid pTal into the 
glioblastoma cell lines U87-MG, U118-MG and U373-MG. After 24 hour cells were 
harvested, the amounts of protein and β-galactosidase measured. Identical amounts of 
protein were then used for a secreted alkaline phosphatase assay and the assay results 
normalized to the specific activity of β-galactosidase. The results are presented in Fig.1 and 
demonstrate that the levels of AP-1 were significantly elevated in both U87-Mg and U118-
MG cells. U373-MG cells did not have elevated levels of SEAP indicating that they did not 
have activated Ap-1 (data not shown). The AP-1 activity was sensitive to genistein 
indicating the possible involvement of a tyrosine kinase in activating the AP-1 pathway. We 
have obtained similar results with NF-κB activation (6). When compared to a control cell 
line, MCF-10A, which is a cell line derived from normal breast epithelium, U87-MG and 
U118-MG Ap-1 levels also appeared elevated (data not shown). 
Although it was clear that AP-1 levels were elevated at least in the two glioblastomas cell 
lines it was not clear which of the family members of AP-1 might be present and the 
contribution that each family member was making. To determine what roles each individual  
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Fig. 1. AP-1 is elevated in the glioblastoma cell lines U87-MG and U118-MG. Cells were co-
transfected with either the pTAL (black bars), or pAP1SEAP (diagonal striped bars), or 
pAP1SEAP in the presence of genistein (horizontal striped bars) and a plasmid that 
constitutively expressed the β-galactosidase protein. Media was assayed for the presence of 
secreted alkaline phosphatase and the values were normalized to the specific activity of β− 
galactosidase levels from cell lysates. Levels of SEAP in pAP1SEAP transfected cells were 
statistically significantly different from either the pTAL control or the cells treated with  
genistein (p0.05). 
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shRNA sequences. Sequences for the shRNAs are given in table 1.  
 
Table 1. Sequences of the siRNAs that were synthesized. The designation of c indicates 
control oligonucleotides that are scrambled. Note that the overhanging ends are compatible 
with HindII and BglII sites in the vectors that were used. 
family member might be playing in the increased levels of AP-1 we designed a series of 
shRNAs that were directed specifically to each individual family member (Table 1). We then 
tested these constructs in both transient expression and in stable expression assays. Western 
blotting demonstrated that all of the family members were present in the U87-MG cells that 
there were no family members that were expressed. Furthermore, levels of these proteins 
could be reduced with either transient or stable expression studies as compared to cognate 
controls (Fig. 2). 
To determine what effect, if any, this reduction in protein might have on AP-1 activity we 
transfected into cells the pAP1-SEAP reporter plasmid or its control pTAL. From this assay 
it became apparent that the contributions that the different AP-1 family members had on 
AP-1 levels were quite variable and ranged from a low of 7% for JunB to 84% for c-Fos.  
We were interested what the affect was of inhibiting these proteins would have on the cells 
in stable assays. Transient transfections could only allow us to assay the affects of the 
shRNA constructs on a potentially minor proportion of the population of cells. By creating 
stable transfectants we could investigate the role of some of these proteins consistently 
within a population. The shRNAs for c-Jun and c-Fos were cloned into a modified pSuperior 
neo vector that we created so that it expressed the hygromycin resistance gene in place of  
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Fig. 2. Expression of AP-1 family members transiently transfected with plasmids that either 
expressed shRNA or the scrambled control shRNA. Cels were transfected with indicated 
plasmids and lysates were tested for expression of the various family members by western 
blot analysis of whole cell lysates. Cells were also transfected with the pAP1SEAP reporter 
plasmid and the media assayed for SEAP. 
           55% 
           55% 
Reduction in AP-1 activity 
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Fig. 3. Stable transfection and inhibition of cell doubling with c-Jun and c-Fos shRNAs. U87-
MG cells that expressed the pTET-ON plasmid were transfected with the pSuperior 
constructs of the shRNAs for c-Jun and c-fos shRNAs or their cognate controls. Cells 
selected in hygromycin were then tested for their ability to replicate in the presence or 
absence of the inducer for shRNA, doxtcyclin. In both cases day 6 values are statistically 
significantly different between the control and shRNA expressing cells (p<0.05). 
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the neo resistance gene. The promoter in this vector that drives the expression of the 
shRNAs is an H1 promoter that has additional sequences that make is responsive to the Tet 
repressor. Cell lines of U87-MG were created that expressed the Tet repressor and these 
were transfected and selected so that they also carried either the c-Fos or c-Jun shRNAs that 
were used in the transient assays described above. As expected induction of the shRNA 
expression with doxycycline resulted in depression of c-Jun (90%) and c-Fos (98%) protein 
levels as compared to their uninduced controls (Fig. 3a). To determine what effect this type 
of reduction would have on the ability of the cells to divide cells were treated with 
doxycycline and their division measured over a period of several days using a formazan dye 
derivative. The results (Fig. 3b) demonstrate that a reduction in c-Fos and c-Jun did have a 
modest but statistically significant suppressive affect on cell division which was not seen in 
the cells that were transfected with the scrambled control oligonucleotides. If doxycycline 
was removed part way through the assay this effect was not seen indicating that the effect 
could be cytostatic as opposed to resulting in apoptosis or cell death. However, western 
blots of the cell lines demonstrated that they had increased levels of cleaved PARP and 
caspase 3,7 activity indicating that at least some of the cells were undergoing apoptosis in 
response to expression of the shRNAs. 
4. Discussion 
AP-1 is a transcription factor that is frequently up regulated in a variety of tumors. In this 
study we determined that AP-1 is up regulated in some glioblastoma cell lines. 
Transcription factors are typically defined by the sequences that they are capable of binding  
even though the transcription factor itself may be composed of several different but related 
polypeptides. The purpose of this study was to determine if the cell lines that expressed 
higher levels of activated AP-1 only expressed certain family members. Similar to what we 
previously found with the NF-κB family of transcription factors (6), most if not all of the 
family members of AP-1 were present in these cells and they appeared to play a role in the 
level of AP-1 that was found within the cell. Although inhibition of c-Jun, JunD, c-Fos, FosB, 
Fra-1 and 2 all had similar effects on the levels of AP-1, inhibition of JunB did not have a 
substantial impact on AP-1 levels indicating that certain family members were not as 
important for the AP-1 effect on the cells. This is in contrast to previous findings that JunB 
had an antagonistic effect to c-Jun on cells (4). Whether our results differ due to the fact that 
we used established cell lines as opposed to fresh tumor tissue is unclear.   
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